Lennox-Gastaut Syndrome (LGS) is considered as an epileptic encephalopathy and is defined by a triplet of multiple drug-resistant seizure types, a specific EEG configuration presenting bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability. According to the National Institute of Health, LGS is a form of severe epilepsy that originates in childhood and is characterized by multiple types of seizures and intellectual disability.
DelveInsight's "Lennox-Gastaut Syndrome (LGS) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Lennox-Gastaut Syndrome (LGS) market Size and Share, historical and forecasted epidemiology analysis as well as the Lennox-Gastaut Syndrome (LGS) market trends in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Lennox-Gastaut Syndrome (LGS) Market Key Facts
As per DelveInsight estimates, total diagnosed prevalent cases of LGS in the 7MM was found to be 68,811 in 2017. Among all the countries, the estimates show a higher population of LGS in the United States with 31,925 cases in 2017.
As per DelveInsight estimates, among the 7MM, Japan had the lowest diagnosed prevalent population of LGS in 2017.
Males are more prone to LGS than females among all countries. In 2017, there were 23,597 prevalent cases of LGS in males and 8,328 prevalent cases in females in the United States as per DelveInsight’s analysts assessments
Lennox-Gastaut Syndrome (LGS) Market
As per DelveInsight assessments in the 7MM countries, the United States accounts for the highest market size of LGS in comparison with EU5 and Japan. The market size of Lennox-Gastaut Syndrome (LGS) is expected to increase during the forecast period, Owing to the launch of upcoming therapies.
The Lennox-Gastaut Syndrome (LGS) market analysis report helps to build the detailed comprehension of the historic, current and forecasted Lennox-Gastaut Syndrome (LGS) market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
Lennox-Gastaut Syndrome (LGS) Epidemiology
The Lennox-Gastaut Syndrome (LGS) epidemiology analysis covers insights about historical and current Lennox-Gastaut Syndrome (LGS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Lennox-Gastaut Syndrome (LGS) Drugs Uptake and Key Market Players
The Lennox-Gastaut Syndrome (LGS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lennox-Gastaut Syndrome (LGS) market or expected to get launched in the market during the study period. The analysis covers Lennox-Gastaut Syndrome (LGS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the LGS market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period.
Some of the key companies in the Lennox-Gastaut Syndrome (LGS) market includes:
Lundbeck
Greenwich Biosciences
Janssen Pharmaceuticals
Eisai
Zogenix International Ltd. (a subsidiary of Zogenix)
Takeda
Ovid
And many others.
Drugs Covered
Onf
Epidiolex
Banzel
Fycompa
ZX 008
TAK-935/ OV935
And others.
For more information on Lennox-Gastaut Syndrome (LGS) Market, visit:
https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market